Erfan Taherifard

MD MPH I Postdoctoral Associate at Yale University I Academic Editor at PLOS One I Aspiring Internist @YaleMed @Yale_CRRIT @YODAProject @PLOSOne

[Homa Majd @homamajd]

I’m excited to share that we are looking for a postdoctoral researcher to join my lab at Yale.

If you, or someone you know, might be interested, please feel free to reach out or share this post.

https://t.co/rllwrIdQmm

[Peer Review Congress #PRC11 Coming 2029! @peerrevcongress]

Data repositories provide a mechanism for deposition of clinical trial artefacts in a centralised structure staffed by people who evaluate requests, secure data use agreements, and take other steps to ensure responsible use.
@MichelleM_Mello @StanfordLaw @bmj_latest

[Yale CRRIT @Yale_CRRIT]

In February 2026, former FDA leadership announced via journal publication a consequential shift away from basing drug approval on two or more clinical trials to just one (1/7)

[The BMJ @bmj_latest]

Structured data sharing mechanisms can support additional secondary use of clinical trial data, finds study @jsross119
https://t.co/QQJkSD2XQF

Linked commentary
https://t.co/EF5NFDHwDW

[Erfan Taherifard @ETaherifard]

Grateful to my mentors, coauthors, and collaborators at @YaleMed, @YODAProject, and Johnson & Johnson who made this work possible.

#OpenScience #DataSharing #ClinicalTrials

[Erfan Taherifard @ETaherifard]

I’m excited to share our new study, published today in @bmj_latest, examining the long-term scientific value generated through the secondary use of clinical trial data.

https://t.co/C4AJJgr90e

[Erfan Taherifard @ETaherifard]

The contribution of external investigators increased over time, exceeding half of all secondary publications by 11 years after primary publication.

They more often conducted pooled analyses, predictive or prognostic modelling, and statistical methods research.

[BMJ Oncology @BMJOncology]

The long return on discovery science in cancer therapeutics

Many advances in cancer treatment depend on discoveries made decades earlier

https://t.co/vgxIjrDSWh

[The BMJ @bmj_latest]

A drug for advanced pancreatic cancer that trial results showed nearly doubled overall survival time in patients who were previously treated with chemotherapy has been approved in the US
https://t.co/huJla9iIDA

[Evangelos K. Oikonomou @ekoikonomou]

We are hiring! 🚨

Our group at @YaleCardiology @YaleIMed is recruiting a #postdoc in cardiovascular #AI.

The position is partly funded through @WellcomeLeap #VISIBLE. Help us use multimodal AI to identify underrecognized cardiovascular disease.

🔗https://t.co/gIRWHrGjwA

@cards_lab @rohan_khera @samitshahmd

[JAMA @JAMA_current]

📊 JAMA Guide to Statistics and Methods: Difference-in-differences compares pre-to-post changes between intervention and comparison groups, controlling for baseline differences and trends, and requires careful evaluation of the parallel trends assumption.

https://t.co/rQq79vL85k

[JAMA Health Forum @JAMAHealthForum]

Biologics and therapeutics from larger companies reached #MostFavoredNation markets sooner than small-molecule drugs and products from smaller companies, which may affect Medicare pricing benchmarks under GLOBE and GUARD.

https://t.co/1D3jhz3ozb

[Reshma Ramachandran @reshmagar]

Unsurprisingly those with known conflicts of interest on the @US_FDA Pharmacy Compounding Advisory Committee vote in favor of including the peptide BPC-157 on the 503A bulks list allowing for unregulated products to be marketed & dispensed to patients: https://t.co/Xm9wfPu1T2

[Yale CRRIT @Yale_CRRIT]

Now out in @JAMA_current is our new secret shopper study characterizing how patients experience online prescribing of GLP-1 receptor agonists from telehealth platforms (1/13)

[Reshma Ramachandran @reshmagar]

Thanks @KatieMPalmer @statnews for this terrific reporting on our secret shopper study out today on @JAMA_current. Couldn't agree more: "On many telehealth sites, 'the priority is on the sale of the medication, not the patient,' said William H. Dietz..." https://t.co/5qmV1Njd7T

[Retraction Watch @RetractionWatch]

Ethics journal retracts paper by high school student for AI, peer review manipulation.
https://t.co/Xzq7f9YMuY

[America @america]

🇺🇸🇺🇸 Happy 4th of July 🇺🇸🇺🇸

[Health Affairs @Health_Affairs]

Offering proposals to improve the FDA’s guidance to implement a new approval framework for individualized genetic therapies based on a “plausible mechanism” of action. | Forefront

@HollyLynchez, et al. | @PennMEHP

https://t.co/2J4bloJgR2